CNS5:Pleomorphic xanthoastrocytoma: Difference between revisions
| Line 71: | Line 71: | ||
|Telomerase activation (mainly in anaplastic PXA) | |Telomerase activation (mainly in anaplastic PXA) | ||
|TERT promoter mutations/amplifications | |TERT promoter mutations/amplifications | ||
| | |Recurrent (15–47% in anaplastic)<ref>{{Cite journal|last=Phillips|first=Joanna J.|last2=Gong|first2=Henry|last3=Chen|first3=Katharine|last4=Joseph|first4=Nancy M.|last5=van Ziffle|first5=Jessica|last6=Bastian|first6=Boris C.|last7=Grenert|first7=James P.|last8=Kline|first8=Cassie N.|last9=Mueller|first9=Sabine|date=2019-01|title=The genetic landscape of anaplastic pleomorphic xanthoastrocytoma|url=https://pubmed.ncbi.nlm.nih.gov/30051528|journal=Brain Pathology (Zurich, Switzerland)|volume=29|issue=1|pages=85–96|doi=10.1111/bpa.12639|issn=1750-3639|pmc=7837273|pmid=30051528}}</ref> PMID: 30051528 | ||
|P (poor; recurrence risk) | |P (poor; recurrence risk) | ||
|Yes (WHO, NCCN-context specefic) | |Yes (WHO, NCCN-context specefic) | ||